The observation that T lymphomas have high expression of this receptor whereas normal cells (other than subsects of regulatory and activated T lymphocytes) do not show its expression has led to the development of novel CD25-directed treatment strategies (6). The gene discussed is IL2RA; the disease is lymphoma.